FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2500736086> ?p ?o ?g. }

• W2500736086 endingPage "186" @default.
• W2500736086 startingPage "1" @default.
• W2500736086 abstract "Introduction and Objectives: Inhibitor development in nonsevere haemophilia A patients (FVIII:C, 2-40 IU/dL) has a heterogeneous clinical phenotype, ranging from irrelevant transient inhibitors to high titre neutralizing antibodies with severe bleeding complications. Data on inhibitor presentation are scarce and selected, favouring those with severe complications. The aim of current study was to describe the presenting symptoms of inhibitors in a large unselected cohort of nonsevere haemophilia patients. Materials and Methods: Clinical data were collected of 107 inhibitor patients derived from a source population of 2,709 nonsevere haemophilia A patients that were treated between 1980 and 2011 in 34 European and Australian centers (the INSIGHT consortium). Patients were subdivided according to age and calendar period at time of inhibitor development (10-year groups), aiming to search for age-related trends and trends over time. Results: Age at inhibitor detection varied widely between 1 and 85 years with a median age of 38 years (IQR, 15-61). Most inhibitors developed in the period of 2000-2010 (n = 64, 60%). Inhibitors developed after a median of 28 exposure days (IQR, 14-66), which was comparable between all age groups. Fifty-seven patients (56%) had high titre inhibitors (>5 BU/mL). About half of the high titre inhibitors developed in patients older than 40 years (n = 30, 53%) and 60% after the year 2000 (n = 34). In 13 (12%) inhibitor patients the inhibitor was detected during routine laboratory screening and no clinical signs of the inhibitor were present. More than half of the patients (n = 61) had an increased bleeding tendency at presentation with inhibitor. In 80 patients (80%) endogenous FVIII:C was decreased to below 5 IU/dL (including 33/44 patients with low titer inhibitors), of whom FVIII:C fell below ≤ 0.01 IU/mL in 49 patients (46%). Conclusion: Half of the patients with nonsevere haemophilia A and inhibitors developed high titre inhibitors; these were more common in the last decennium. More than half of the patients presented with bleeding complications and 46% had changed to a severe phenotype. These results stress the importance of close follow-up after exposure to therapeutic factor VIII concentrates in nonsevere haemophilia A patients." @default.
• W2500736086 created "2016-08-23" @default.
• W2500736086 creator A5002870795 @default.
• W2500736086 creator A5006881585 @default.
• W2500736086 creator A5008435049 @default.
• W2500736086 creator A5010472135 @default.
• W2500736086 creator A5012257541 @default.
• W2500736086 creator A5013522339 @default.
• W2500736086 creator A5013966252 @default.
• W2500736086 creator A5014111921 @default.
• W2500736086 creator A5015488050 @default.
• W2500736086 creator A5017460000 @default.
• W2500736086 creator A5018946153 @default.
• W2500736086 creator A5020803544 @default.
• W2500736086 creator A5021470371 @default.
• W2500736086 creator A5026508522 @default.
• W2500736086 creator A5028579712 @default.
• W2500736086 creator A5032368908 @default.
• W2500736086 creator A5033498450 @default.
• W2500736086 creator A5034014065 @default.
• W2500736086 creator A5034218391 @default.
• W2500736086 creator A5035541059 @default.
• W2500736086 creator A5035546452 @default.
• W2500736086 creator A5036282387 @default.
• W2500736086 creator A5037269281 @default.
• W2500736086 creator A5040709798 @default.
• W2500736086 creator A5043026808 @default.
• W2500736086 creator A5048976347 @default.
• W2500736086 creator A5052574929 @default.
• W2500736086 creator A5053532854 @default.
• W2500736086 creator A5055565211 @default.
• W2500736086 creator A5056630421 @default.
• W2500736086 creator A5059264212 @default.
• W2500736086 creator A5060330439 @default.
• W2500736086 creator A5064382304 @default.
• W2500736086 creator A5066305508 @default.
• W2500736086 creator A5067175961 @default.
• W2500736086 creator A5069096181 @default.
• W2500736086 creator A5071869697 @default.
• W2500736086 creator A5075635630 @default.
• W2500736086 creator A5079861916 @default.
• W2500736086 creator A5079993239 @default.
• W2500736086 creator A5080634466 @default.
• W2500736086 creator A5082030485 @default.
• W2500736086 creator A5082783229 @default.
• W2500736086 creator A5085526211 @default.
• W2500736086 creator A5086164760 @default.
• W2500736086 creator A5086880724 @default.
• W2500736086 creator A5090611983 @default.
• W2500736086 date "2014-04-25" @default.
• W2500736086 modified "2023-10-18" @default.
• W2500736086 title "Abstracts" @default.
• W2500736086 doi "https://doi.org/10.1111/hae.12400" @default.
• W2500736086 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24762218" @default.
• W2500736086 hasPublicationYear "2014" @default.
• W2500736086 type Work @default.
• W2500736086 sameAs 2500736086 @default.
• W2500736086 citedByCount "2" @default.
• W2500736086 countsByYear W25007360862015 @default.
• W2500736086 countsByYear W25007360862019 @default.
• W2500736086 crossrefType "journal-article" @default.
• W2500736086 hasAuthorship W2500736086A5002870795 @default.
• W2500736086 hasAuthorship W2500736086A5006881585 @default.
• W2500736086 hasAuthorship W2500736086A5008435049 @default.
• W2500736086 hasAuthorship W2500736086A5010472135 @default.
• W2500736086 hasAuthorship W2500736086A5012257541 @default.
• W2500736086 hasAuthorship W2500736086A5013522339 @default.
• W2500736086 hasAuthorship W2500736086A5013966252 @default.
• W2500736086 hasAuthorship W2500736086A5014111921 @default.
• W2500736086 hasAuthorship W2500736086A5015488050 @default.
• W2500736086 hasAuthorship W2500736086A5017460000 @default.
• W2500736086 hasAuthorship W2500736086A5018946153 @default.
• W2500736086 hasAuthorship W2500736086A5020803544 @default.
• W2500736086 hasAuthorship W2500736086A5021470371 @default.
• W2500736086 hasAuthorship W2500736086A5026508522 @default.
• W2500736086 hasAuthorship W2500736086A5028579712 @default.
• W2500736086 hasAuthorship W2500736086A5032368908 @default.
• W2500736086 hasAuthorship W2500736086A5033498450 @default.
• W2500736086 hasAuthorship W2500736086A5034014065 @default.
• W2500736086 hasAuthorship W2500736086A5034218391 @default.
• W2500736086 hasAuthorship W2500736086A5035541059 @default.
• W2500736086 hasAuthorship W2500736086A5035546452 @default.
• W2500736086 hasAuthorship W2500736086A5036282387 @default.
• W2500736086 hasAuthorship W2500736086A5037269281 @default.
• W2500736086 hasAuthorship W2500736086A5040709798 @default.
• W2500736086 hasAuthorship W2500736086A5043026808 @default.
• W2500736086 hasAuthorship W2500736086A5048976347 @default.
• W2500736086 hasAuthorship W2500736086A5052574929 @default.
• W2500736086 hasAuthorship W2500736086A5053532854 @default.
• W2500736086 hasAuthorship W2500736086A5055565211 @default.
• W2500736086 hasAuthorship W2500736086A5056630421 @default.
• W2500736086 hasAuthorship W2500736086A5059264212 @default.
• W2500736086 hasAuthorship W2500736086A5060330439 @default.
• W2500736086 hasAuthorship W2500736086A5064382304 @default.
• W2500736086 hasAuthorship W2500736086A5066305508 @default.
• W2500736086 hasAuthorship W2500736086A5067175961 @default.
• W2500736086 hasAuthorship W2500736086A5069096181 @default.
• W2500736086 hasAuthorship W2500736086A5071869697 @default.

• next